Most patients on a GLP-1 do not need to stop the medication before surgery. The 2024 multisociety guidance changed that conversation — but only if the surgical team is told.
A patient who is scheduled for elective surgery and has been taking semaglutide or tirzepatide for weight loss is in a different clinical position than they were two years ago. In June 2023, the American Society of Anesthesiologists issued the first formal guidance on GLP-1 medications and anesthesia, and the message was conservative: hold the dose before the procedure. In October 2024, the ASA — along with the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the Society of American Gastrointestinal and Endoscopic Surgeons, and the International Society of Perioperative Care of Patients with Obesity — released updated multisociety guidance that walked that position back substantially. A 2025 consensus from the Society for Perioperative Assessment and Quality Improvement, published in the British Journal of Anaesthesia, reinforced the new direction.
The current standard of care, in plain language: most patients can continue their GLP-1 medication before elective surgery, provided the surgical team is informed and a few specific precautions are taken. What matters far more than the timing of the last dose is what the patient discloses, and when.
This is a practical guide to that disclosure, the risk factors clinicians weigh, and the protocol most US anesthesia teams are now using.
Why GLP-1s matter at the time of surgery
The mechanism that makes semaglutide and tirzepatide effective for weight loss is the same one that creates a perioperative consideration. GLP-1 receptor agonists slow gastric emptying. Food and fluid that would normally clear the stomach within a few hours can sit longer, sometimes well beyond the standard preoperative fasting window of eight hours for solids and two hours for clear liquids.
The clinical concern is aspiration: stomach contents passing up the esophagus during induction of anesthesia and entering the airway. Aspiration is rare under modern anesthetic technique, but when it happens it can cause aspiration pneumonia, chemical pneumonitis, and in rare cases more serious complications. The 2023 ASA guidance was issued in response to a small number of case reports of regurgitation events in GLP-1 patients, which the society judged worth flagging while the literature caught up.
The literature has since matured. Multiple cohort studies and a large 2025 analysis found that, while GLP-1 patients do have measurably more residual gastric content after standard fasting compared to non-users, actual aspiration events in this population are rare and not consistently shown to be more frequent than in matched controls. The clinical picture is one of a small absolute risk that can be further reduced by extending the fasting window and adjusting anesthetic technique.
What the updated guidance actually says
The 2024 multisociety guidance and the 2025 SPAQI consensus converge on three principles:
- Most patients should continue their GLP-1 medication perioperatively. Stopping the medication carries its own costs — glycemic instability for patients using GLP-1s for diabetes, disruption to weight management, and the logistical and financial burden of restart. The default is to continue.
- The exception is patients with active gastrointestinal symptoms. Severe nausea, vomiting, inability to tolerate oral intake, or significant abdominal pain at the time of surgery indicate the medication is having an outsized effect on gastric motility. In those cases, the surgical team should treat the patient as having a full stomach and adjust anesthesia technique accordingly — or, where the procedure is elective, consider delaying.
- All patients on GLP-1s benefit from extended fasting. The 2025 SPAQI consensus recommends a 24-hour clear-liquid diet before any procedure requiring anesthesia. This is longer than the standard NPO window and is the single most important practical change in the new guidance.
A few national and institutional guidelines remain more conservative. The Brazilian Society of Diabetes recommends holding semaglutide for 21 days and tirzepatide for 15 days before elective surgery, based on pharmacokinetic principles. Some US hospital systems still default to a one-week hold for weekly formulations. The 2025 UK Association of Anaesthetists consensus, by contrast, recommends continuing GLP-1s throughout the perioperative period. The guidance is converging but not yet uniform.
What this means for a patient: the institution doing your surgery may have its own protocol, and that protocol governs. The role of the patient is to disclose early, follow the team’s specific instructions, and not improvise.
Who is at higher risk and needs extra precaution
Risk in this setting is not binary. The same patient on the same medication can be lower or higher risk depending on a handful of clinical variables. The factors most associated with delayed gastric emptying — and therefore the patients most likely to need an individualized plan — include:
- Recent dose escalation. Patients in the titration phase, where the dose is still increasing every few weeks, tend to have more pronounced effects on gastric motility than patients who have been stable on a maintenance dose for months.
- Weekly versus daily formulations. Weekly injectables — semaglutide and tirzepatide — carry residual pharmacologic effect for longer than daily oral formulations.
- Higher current dose. Effects are dose-dependent. A patient on semaglutide 2.4 mg weekly has more pronounced gastric slowing than a patient on 0.5 mg.
- Active GI symptoms. Nausea, vomiting, abdominal fullness, or early satiety in the days before surgery are clinical signs the medication is producing significant gastric effects.
- Comorbid conditions that slow gastric emptying. Diabetes (particularly with autonomic neuropathy), Parkinson’s disease, chronic opioid use, and prior gastric surgery all compound the risk.
- Procedures with higher inherent aspiration risk. Cases requiring deep sedation rather than general anesthesia with a secured airway, prone positioning, or procedures involving the upper GI tract require additional consideration.
A patient who fits one or more of these categories is not necessarily told to stop the medication. They are flagged for additional precautions — typically the 24-hour clear-liquid diet, the use of rapid-sequence induction technique, point-of-care gastric ultrasound on the day of surgery, or some combination of these.
What to actually tell your anesthesiologist
The single most important action a patient can take is full, early disclosure of GLP-1 use. The reason this gets missed is that many patients do not think of weight-loss medication as a medication in the same category as a blood thinner or a beta blocker. They forget to list it, or assume the surgical team already knows from the medical record. Both assumptions are wrong often enough that anesthesia societies have specifically asked patients to volunteer the information.
A useful disclosure script, at the preoperative appointment and again on the day of surgery:
- The exact medication name (e.g., compounded semaglutide, compounded tirzepatide, brand-name versions if applicable)
- The current dose (e.g., 1.0 mg weekly, 5 mg weekly)
- How long you have been on this medication and at this dose
- The date and time of your most recent dose
- Whether you have had any recent GI symptoms — nausea, vomiting, fullness, reduced appetite beyond your usual
- The contact information for the physician prescribing the medication, in case the surgical team wants to coordinate
If you are an Elara patient, your prescribing physician, medication, and dosing history are on record through the program, and that information can be shared with your surgical team in advance of your procedure. This is one of the practical reasons physician-guided telehealth care matters at moments like this — there is a clinician on record who can be reached, rather than a faceless pharmacy or app.
How the protocol varies by procedure
Not every procedure carries the same aspiration risk, and the precautions are calibrated to the case.
Elective surgery under general anesthesia
This is the scenario the 2024 guidance is built around. Most patients continue the medication, complete a 24-hour clear-liquid diet, and the anesthesia team plans for the possibility of delayed gastric emptying — sometimes adjusting technique to rapid-sequence induction or using point-of-care gastric ultrasound to confirm an empty stomach before induction.
Colonoscopy and upper endoscopy
These procedures already involve a prolonged liquid-only preparation, which works in the patient’s favor. The 24-hour clear-liquid diet is generally built into the standard colonoscopy prep. For upper endoscopy, where the scope passes directly through the area of concern, the team may be more conservative and elect to hold a weekly GLP-1 for one dose cycle. For the colonoscopy-specific protocol — including how GLP-1s interact with bowel prep quality — see our dedicated guide to GLP-1 before a colonoscopy.
Dental and cosmetic procedures with sedation
Procedures done under moderate-to-deep sedation rather than general anesthesia — wisdom-tooth extraction, certain cosmetic procedures, IV-sedation dental work — sit in a middle zone. The aspiration risk is real because the airway is not always secured, but the procedures are typically brief. Many dental and cosmetic teams now follow the SPAQI 24-hour clear-liquid recommendation. Patients should expect to be asked about GLP-1 use at the consultation and again at check-in.
Emergency or urgent surgery
When surgery cannot be delayed, the medication cannot be held in advance, and the standard fasting window cannot be extended. In those cases the surgical team treats the patient as having a full stomach by default and uses rapid-sequence induction with cricoid pressure, or other techniques appropriate to the case. The patient’s job in an emergency is simple: tell anyone in scrubs that you are on a GLP-1, what dose, and when your last injection was. The team handles the rest.
Restarting after surgery
The restart is rarely discussed publicly, but it matters. The principles most surgical and prescribing teams follow:
- Resume only when you can reliably tolerate oral intake. Vomiting in the immediate post-operative period is common from anesthesia itself, and a GLP-1 dose layered onto that can prolong the nausea unnecessarily.
- Resume at the same dose, not a higher one. If a dose was missed during the perioperative window, it is generally safer to pick up at the prior dose than to skip ahead.
- Coordinate with your prescribing physician. A short delay of one or two dose cycles is medically inconsequential for most patients and lets the GI tract settle before reintroducing pharmacologic slowing.
For weekly formulations, missing one or two doses around the surgical window is well within the normal pharmacokinetic margin and does not require a re-titration in most cases.
A final framing
The 2024 multisociety guidance changed the question for GLP-1 patients facing surgery. The question is no longer “should I stop?” — for most patients, the answer is no. The question is “did I disclose, and did the team plan accordingly?” The aspiration concern that drove the 2023 guidance is real but small in absolute terms, and it is meaningfully reduced by two simple things: early communication with the surgical team and a 24-hour clear-liquid diet before the procedure.
The patients who run into trouble are almost always patients who did not tell anyone they were on a GLP-1, or who told the team late enough that the protocol could not be adjusted. The patients who do well are almost always patients who disclosed at the preoperative visit, brought a written list of their medications and doses, and followed the institution-specific fasting instructions.
Elara’s physician-guided program keeps a board-certified physician on record for every patient, along with a complete medication and lab history. Patients planning an elective procedure can request that information through the program in advance of their surgical appointment, and share it with their surgical and anesthesia team as part of preoperative disclosure.
Frequently asked questions
Do I have to stop my GLP-1 before surgery? For most patients, no. The 2024 multisociety guidance recommends continuing the medication and applying additional precautions — most commonly a 24-hour clear-liquid diet before the procedure. Patients with active GI symptoms (severe nausea, vomiting, inability to tolerate oral intake) or other risk factors may be advised to hold a dose. The decision is made with your surgical team.
How long should I be on clear liquids before surgery? The 2025 SPAQI consensus recommends 24 hours of clear liquids before any procedure requiring anesthesia for patients on GLP-1 medications. Some institutions remain more conservative and may extend this. Follow your surgical team’s specific instructions, which override any general guidance.
What if I am on compounded semaglutide or tirzepatide instead of a brand-name medication? Compounded semaglutide and compounded tirzepatide work through the same pharmacologic mechanism — delayed gastric emptying — as any other GLP-1 medication. Your surgical team should plan for the same perioperative considerations regardless of whether the prescription is brand-name or compounded. Disclose the medication name, the strength, and the dose.
Should I tell my dentist or cosmetic surgeon about my GLP-1? Yes. Any procedure involving sedation or anesthesia warrants the same disclosure as a major surgery. Dental teams and cosmetic offices increasingly ask about GLP-1 use at intake and may follow the same 24-hour clear-liquid recommendation.
What happens in an emergency where I cannot stop the medication? Emergency surgery proceeds. The anesthesia team plans for a full stomach by default and uses techniques — rapid-sequence induction, cricoid pressure — that reduce aspiration risk in patients who cannot fast. Your job is to disclose the medication name and most recent dose to anyone in scrubs as early in the process as possible.
When can I restart my GLP-1 after surgery? Most prescribing physicians restart at the same dose once a patient can tolerate oral intake reliably and the immediate post-anesthesia nausea has resolved. For weekly formulations, missing one or two doses around the surgical window does not require a re-titration. Coordinate the restart with your prescribing physician.
This article is intended for general educational purposes and does not constitute medical advice. Always consult a physician before making changes to a prescribed medication regimen, and disclose all medications — including GLP-1 receptor agonists — to your surgical and anesthesia team well in advance of any procedure. Specific institutional protocols override general guidance.